Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.39 USD | +1.33% | +3.26% | +1.42% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Financials (USD)
Sales 2024 * | 663M | Sales 2025 * | 166M | Capitalization | 9.06B |
---|---|---|---|---|---|
Net income 2024 * | 4.25B | Net income 2025 * | -1.01B | EV / Sales 2024 * | 5.14 x |
Net cash position 2024 * | 5.65B | Net cash position 2025 * | 4.39B | EV / Sales 2025 * | 28.1 x |
P/E ratio 2024 * |
2.17
x | P/E ratio 2025 * |
-8.57
x | Employees | 904 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.81% |
Latest transcript on Roivant Sciences Ltd.
1 day | +0.27% | ||
1 week | +3.31% | ||
Current month | +3.12% | ||
1 month | +2.93% | ||
3 months | +13.65% | ||
6 months | +24.06% | ||
Current year | +0.09% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Gline
CEO | Chief Executive Officer | 40 | 16-02-29 |
Richard Pulik
DFI | Director of Finance/CFO | - | 21-09-27 |
Eric Venker
PSD | President | 37 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 53 | 23-03-12 | |
Keith Manchester
BRD | Director/Board Member | 55 | 13-12-31 |
Dan Gold
BRD | Director/Board Member | 56 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 11.39 | +1.33% | 3 692 432 |
24-05-02 | 11.24 | +0.27% | 3,331,130 |
24-05-01 | 11.21 | +2.84% | 5,558,234 |
24-04-30 | 10.9 | -2.07% | 4,553,208 |
24-04-29 | 11.13 | +0.91% | 5,224,715 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.09% | 9.06B | |
+29.68% | 681B | |
+25.07% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+14.68% | 235B | |
+4.71% | 199B | |
-12.43% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- ROIV Stock